Teva Pharmaceuticals has successfully completed its $6.2bn acquisition of Cephalon following approval from European regulators.

Following the European Commission approval, Teva will divest marketing rights in France for a generic version of Cephalon narcolepsy medication Provigil.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The move comes after US authorities requested that Teva allow Par Pharmaceuticals to market a separate generic copy of Provigil for a year.

The acquisition has been designed to allow Teva to offset revenue losses associated with the patent expiry of multiple sclerosis drug Copaxone, the company’s biggest selling product.